KBKen Bassett

Ken Bassett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ken Bassett has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Appropriate glycated haemoglobin testing frequency to monitor patients with type 2 diabetes

    by Wade Thompson, Tom Perry, Guillaume Grenet, Ken Bassett, Anshula Ambasta

    Glycated haemoglobin (HbA1c) is used to monitor glycaemic control among patients with type 2 diabetes (T2DM). Glycated haemoglobin represents a 3-month glycaemic average, with the most recent 6 weeks of glycaemia having the greatest influence. Analytical and biological variation introduce imprecision into any single HbA1c, where a result of 7.5% may represent a ‘true’ value between 6.8% and 8.2%. This Therapeutics Letter evaluates the most appropriate interval for monitoring HbA1c in T2DM. Evidence was synthesised from a pragmatic randomised controlled trial (RCT) and three large observational studies. In the RCT, 94% of patients monitored every 6 months maintained good glycaemic control compared to 92% of those monitored every 3 months. Observational data indicated that 3-month testing resulted in a clinically unimportant difference in HbA1c compared with 6-month testing. Furthermore, patients tested 2–3 times annually were as likely to achieve personalised goals as those tested four times per year. Testing more than four times annually was associated with a lower probability of achieving targets. For patients with stable T2DM meeting glycaemic goals, monitoring HbA1c every 6 months is as effective as every 3 months and could be contemplated for many patients following a discussion of patient goals and preferences. Frequent testing may be reserved for periods of medication adjustment, changes in health status or when targets are unmet. Reducing testing frequency in stable patients minimises low-value data, reduces the carbon footprint of lab testing and improves patient convenience without compromising clinical outcomes.

  • Pharmacotherapy for hypertension in adults 60 years or older

    by Vijaya M Musini, Aaron M Tejani, Ken Bassett, Lorri Puil, Wade Thompson, James M Wright

    Rationale This is the third update of a review that was originally published in 1998 and updated in 2009 and 2019. Hypertension increases with age, most rapidly over age 60. It is important to know the benefits and harms of antihypertensive treatment for hypertension in this age group, as well as separately for people 60 to 79 years old and for people 80 years or older. Objectives Primary objective • To assess the effects of antihypertensive drug treatment as compared with placebo or no treatment on all‐cause mortality for people 60 years and older with hypertension defined as systolic blood pressure (SBP) > 140 mmHg or diastolic blood pressure (DBP) > 90 mmHg, or both. Secondary objectives • To assess the effects of antihypertensive drug treatment as compared with placebo or no treatment on cardiovascular‐specific morbidity and mortality in people 60 years and older with hypertension defined as SBP > 140 mmHg or DBP > 90 mmHg, or both. • To assess the rate of withdrawal due to adverse effects of antihypertensive drug treatment as compared with placebo or no treatment in people 60 years and older with hypertension defined as SBP > 140 mmHg or DBP > 90 mmHg, or both. Search methods The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials (RCTs) up to June 2024: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, WHO ICTRP, and ClinicalTrials.gov. We contacted the authors of relevant papers regarding further published and unpublished work. Eligibility criteria RCTs of at least one year's duration comparing antihypertensive drug therapy versus placebo or no treatment and providing morbidity and mortality data for people 60 years and older with hypertension defined as blood pressure greater than 140/90 mmHg. Outcomes Outcomes assessed were all‐cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity and mortality, coronary heart disease morbidity and mortality, and withdrawal due to adverse effects. Risk of bias Two review authors independently assessed risk of bias in the included studies using the Cochrane RoB 1 tool. Synthesis methods We used RevMan for data synthesis and analyses. We based quantitative analyses of outcomes on intention‐to‐treat results. We used risk ratios (RRs) with 95% confidence intervals (CIs) to combine outcomes across trials using a fixed‐effect model. Included studies This update identified no new trials and no ongoing trials. Overall, 16 trials (N = 26,795) in healthy ambulatory adults 60 years or older (mean age 73.8 years) with moderate to severe systolic and/or diastolic hypertension (average 182/95 mmHg) met the inclusion criteria. Most of these trials evaluated first‐line thiazide diuretic therapy for a mean treatment duration of 3.8 years. Synthesis of results Antihypertensive drug treatment reduced all‐cause mortality (10% with treatment versus 11% with control; RR 0.91, 95% CI 0.85 to 0.97; 13 studies, 25,932 participants; high‐certainty evidence); probably reduced cardiovascular morbidity and mortality (10% with treatment versus 14% with control; RR 0.72, 95% CI 0.68 to 0.77; 15 studies, 26,747 participants; moderate‐certainty evidence); probably reduced cerebrovascular mortality and morbidity (3.4% with treatment versus 5.2% with control; RR 0.66, 95% CI 0.59 to 0.74; 13 studies, 26,042 participants; moderate‐certainty evidence); and probably reduced coronary heart disease mortality and morbidity (3.7% with treatment versus 4.8% with control; RR 0.78, 95% CI 0.69 to 0.88; 11 studies, 24,559 participants; moderate‐certainty evidence). Withdrawals due to adverse effects may have increased with treatment (16% with treatment versus 5.4% with control; RR 2.91, 95% CI 2.56 to 3.30; 4 studies, 11,310 participants; low‐certainty evidence). In a sensitivity analysis of the three trials restricted to people with isolated systolic hypertension, reported benefits were similar. We cannot rule out that the observed reduction in all‐cause mortality was due mostly to a reduction in the 60‐ to 79‐year‐old participant subgroup compared with those 80 years or older. The RR for all‐cause mortality in those 60 to 79 years old was 0.86 (95% CI 0.79 to 0.95; 9 studies, 19,017 participants) compared with 0.97 (95% CI 0.87 to 1.10; 8 studies, 6701 participants) in the 80 years or older subgroup, though the test for subgroup difference showed no evidence of a difference. The reduction in cardiovascular mortality and morbidity was due in large part to a reduction in cerebrovascular mortality and morbidity. The most common reason for downgrading the certainty of evidence was risk of bias, in particular incomplete outcome data and selective outcome reporting. Authors' conclusions Treating healthy adults 60 years or older with moderate to severe systolic or diastolic hypertension, or both, with antihypertensive drug therapy reduced all‐cause mortality and probably reduced cardiovascular mortality and morbidity, cerebrovascular mortality and morbidity, and coronary heart disease mortality and morbidity. Most of the evidence pertains to a primary prevention population using a thiazide as first‐line treatment. Given that no new or ongoing trials were identified in this update, the certainty of existing evidence is moderate or high, and we do not expect new trials in the future, this review is considered stable and will no longer be updated. Funding Internal sources. Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia. Office space. External sources. BC Ministry of Health grant to the Therapeutics Initiative. Infrastructure. Registration Original review (1998): Mulrow CD, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 1998, Issue 2. First update (2009): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028/full Second update (2019): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000028.pub3/full


  • Open Access

    Thyroid testing in primary hypothyroidism

    by Anshula Ambasta, Guillaume Grenet, Jessica Otte, Wade Thompson, Kenneth Bassett, Thomas Perry

    Thyroid hormones regulate essential metabolic processes and development. The hypothalamic–pituitary–thyroid axis regulates hormone production, with thyroid-stimulating hormone (TSH) levels being a key indicator of thyroid function in primary hypothyroidism. This therapeutics letter emphasises a TSH-centred approach to the diagnosis and management of primary hypothyroidism (dysfunction at the level of the thyroid gland) in adults. It discourages routine thyroid function screening in asymptomatic individuals due to a lack of demonstrated benefit and potential harm from overdiagnosis and overtreatment. It outlines appropriate diagnostic strategies, including when to use TSH, free T4 (thyroxine), and free T3 (triiodothyronine) tests, and outlines indications for antibody testing. Special considerations are provided for subclinical hypothyroidism and hypothyroidism during pregnancy.


  • Open Access

    Minimising inhaled corticosteroids for COPD

    by Benji Heran, Thomas L. Perry, Ken Bassett

    This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms. Guidelines recommend limiting ICS to severe COPD and only for repeated exacerbations. Studies show withdrawing ICS can be done safely for stable COPD patients with infrequent exacerbations, especially those with lower eosinophil counts. Provincial, national and international guidelines now recommend limiting ICS prescriptions to severe COPD stages. Long-term ICS use may lead to serious side effects, including pneumonia and fractures. Initial COPD therapy should focus on short-acting bronchodilators, not ICS. Adding long-acting bronchodilators is recommended before considering ICS because of limited benefits and risks of serious harms. For persistent symptoms, long-acting muscarinic antagonists (LAMA) or long-acting beta2 agonists (LABA) are recommended, with the addition of ICS reserved for those with repeated exacerbations and severe COPD. Deprescribing ICS can be considered in clinically stable patients, particularly for those with infrequent exacerbations and mild COPD. When applicable, tapering ICS over several months is advised for patients with elevated eosinophil counts. Overall, the risks of serious harms from ICS typically outweigh their limited benefits for mild COPD patients in primary care.


  • Open Access

    Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centres on Service Use: A Pilot Randomized Control Trial from North India (Preprint)

    by Shalinder Sabherwal, Ishaana Sood, Anand Chinnakaran, Gaurav Kumar Garg, Birendra Pratap Singh, Atanu Majumdar, Rajan Shukla, Priya A Reddy, Suzanne Gilbert, Ken Bassett, et al.

    BACKGROUND Vision centres (VC) have developed as an effective primary eyecare delivery model in India. Their financial sustainability is dependent on the number of walk-in patients, spectacle sales, and surgery uptake. Door-to-door vision screening (DTDS) and awareness generation activities were conducted in VC catchments. OBJECTIVE This study analysed the effect of intervention- DTDS, in the catchment population on VC service utilisation. Costs have also been studied. METHODS Randomized, parallel-group experimental study, with a previously published protocol, conducted across our two operational regions having surgical centres and attached VCs. Two rural VCs chosen randomly from each region were further randomized in intervention (DTDS) and control group. The study was designed as a difference-in-difference analysis to examine the proportion of change (from baseline) across the two arms, in average VC walk-in numbers. Patients needing further care after DTDS (intervention arm) or routine community activities (control arm), were referred to the nearby VC. The main outcome variable was the change in average VC attendance per day (November’ 21 to February ’22) as compared to same months in previous year (November’ 20 to February ’21) in both arms. January was excluded to control for high Covid-19 cases. Difference between the two arms was compared. Spectacle and surgical uptake were also assessed. Costs were calculated and compared for- per person screened/referred, per village covered, unit increases in VC walk-in, per patient reporting at VC and per cataract surgery performed among patients referred from VC. RESULTS Less number of villages could be screened in the intervention arm as compared to those visited in the control arm. Average walk-in in the intervention and control arms, increased from 10.4 to 12.3, and 11.5 to 12.2 per day, respectively- a significant increase for both, though the difference between the baseline and study period was significantly more in the intervention. In the intervention arm, significantly more women (46.9% versus 39.9%; p<0.05) and more people with ocular morbidity (95.9% versus 86.1%; p<0.05) visited the VCs as compared to the control arm. Paediatric population had an increase in intervention arm and decrease in control arm. Decrease in proportion of females from baseline was more in control arm than the intervention arm. Compliance to VC referrals was higher in intervention arm. In the intervention arm, the cost per unit increase in VC walk-in was more while the cost per patient reported to VC after referral, was less. CONCLUSIONS DTDS activities increased footfalls at the VC, but at higher cost in the study period. As some of the benefits of DTDS intervention like improvement of gender equity and health seeking behaviour, may not have an impact in short-term, a longer duration study incorporating societal perspective and measuring cost-effectiveness is recommended. CLINICALTRIAL This study was registered and approved as a clinical trial (NCT04800718) during the initial period of data collection, in accordance with ICMJE recommendations. INTERNATIONAL REGISTERED REPORT RR2-10.2196/35824

  • Open Access

    Visual Acuity Screening in North Indian Schools: Testing Accuracy and Cost of Alternate Screening Models

    by Shalinder Sabherwal, Priya Adhisesha Reddy, Zeeshan Siddiqui, Ishaana Sood, Birendra P. Singh, Suma Ganesh, Atanu Majumdar, Ken L. Bassett

    Our study compares the sensitivity, specificity and cost of visual acuity screening as performed by all class teachers (ACTs), selected teachers (STs) and vision technicians (VTs) in north Indian s...


  • Open Access

    Correction: Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centers on Service Use: Protocol for a Randomized Experimental Study

    by Shalinder Sabherwal, Anand Chinnakaran, Ishaana Sood, Gaurav K Garg, Birendra P Singh, Rajan Shukla, Priya A Reddy, Suzanne Gilbert, Ken Bassett, Gudlavalleti V S Murthy, et al.

    [This corrects the article DOI: 10.2196/31951.].

  • Open Access

    Correction: Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centers on Service Use: Protocol for a Randomized Experimental Study (Preprint)

    by Shalinder Sabherwal, Anand Chinnakaran, Ishaana Sood, Gaurav K Garg, Birendra P Singh, Rajan Shukla, Priya A Reddy, Suzanne Gilbert, Ken Bassett, Gudlavalleti V S Murthy

    UNSTRUCTURED A vision center (VC) is a significant eye care service model to strengthen primary eye care services. VCs have been set up at the block level, covering a population of 150,000-250,000 in rural areas in North India. Inadequate use by rural communities is a major challenge to sustainability of these VCs. This not only reduces the community’s vision improvement potential but also impacts self-sustainability and limits expansion of services in rural areas. The current literature reports a lack of awareness regarding eye diseases and the need for care, social stigmas, low priority being given to eye problems, prevailing gender discrimination, cost, and dependence on caregivers as factors preventing the use of primary eye care. Our organization is planning an awareness-cum-engagement intervention—door-to-door basic eye checkup and visual acuity screening in VCs coverage areas—to connect with the community and improve the rational use of VCs. In this randomized, parallel-group experimental study, we will select 2 VCs each for the intervention arm and the control arm from among poor, low-performing VCs (ie, walk-in of ≤10 patients/day) in our 2 operational regions (Vrindavan, Mathura District, and Mohammadi, Kheri District) of Uttar Pradesh. Intervention will include door-to-door screening and awareness generation in 8-12 villages surrounding the VCs, and control VCs will follow existing practices of awareness generation through community activities and health talks. Data will be collected from each VC for 4 months of intervention. Primary outcomes will be an increase in the number of walk-in patients, spectacle advise and uptake, referral and uptake for cataract and specialty surgery, and operational expenses. Secondary outcomes will be uptake of refraction correction and referrals for cataract and other eye conditions. Differences in the number of walk-in patients, referrals, uptake of services, and cost involved will be analyzed. Background work involved planning of interventions and selection of VCs has been completed. Participant recruitment has begun and is currently in progress. Through this study, we will analyze whether our door-to-door intervention is effective in increasing the number of visits to a VC and, thus, overall sustainability. We will also study the cost-effectiveness of this intervention to recommend its scalability. ClinicalTrials.gov NCT04800718; https://clinicaltrials.gov/ct2/show/NCT04800718

  • Open Access

    Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centers on Service Use: Protocol for a Randomized Experimental Study

    by Shalinder Sabherwal, Anand Chinnakaran, Ishaana Sood, Gaurav K Garg, Birendra P Singh, Rajan Shukla, Priya A Reddy, Suzanne Gilbert, Ken Bassett, Gudlavalleti V S Murthy, et al.

    Background: A vision center (VC) is a significant eye care service model to strengthen primary eye care services. VCs have been set up at the block level, covering a population of 150,000-250,000 in rural areas in North India. Inadequate use by rural communities is a major challenge to sustainability of these VCs. This not only reduces the community’s vision improvement potential but also impacts self-sustainability and limits expansion of services in rural areas. The current literature reports a lack of awareness regarding eye diseases and the need for care, social stigmas, low priority being given to eye problems, prevailing gender discrimination, cost, and dependence on caregivers as factors preventing the use of primary eye care. Objective: Our organization is planning an awareness-cum-engagement intervention—door-to-door basic eye checkup and visual acuity screening in VCs coverage areas—to connect with the community and improve the rational use of VCs. Methods: In this randomized, parallel-group experimental study, we will select 2 VCs each for the intervention arm and the control arm from among poor, low-performing VCs (ie, walk-in of ≤10 patients/day) in our 2 operational regions (Vrindavan, Mathura District, and Mohammadi, Kheri District) of Uttar Pradesh. Intervention will include door-to-door screening and awareness generation in 8-12 villages surrounding the VCs, and control VCs will follow existing practices of awareness generation through community activities and health talks. Data will be collected from each VC for 4 months of intervention. Primary outcomes will be an increase in the number of walk-in patients, spectacle advise and uptake, referral and uptake for cataract and specialty surgery, and operational expenses. Secondary outcomes will be uptake of refraction correction and referrals for cataract and other eye conditions. Differences in the number of walk-in patients, referrals, uptake of services, and cost involved will be analyzed. Results: Background work involved planning of interventions and selection of VCs has been completed. Participant recruitment has begun and is currently in progress. Conclusions: Through this study, we will analyze whether our door-to-door intervention is effective in increasing the number of visits to a VC and, thus, overall sustainability. We will also study the cost-effectiveness of this intervention to recommend its scalability. Trial Registration: ClinicalTrials.gov NCT04800718; https://clinicaltrials.gov/ct2/show/NCT04800718 International Registered Report Identifier (IRRID): DERR1-10.2196/31951


  • Open Access

    Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centers on Service Use: Protocol for a Randomized Experimental Study (Preprint)

    by Shalinder Sabherwal, Anand Chinnakaran, Ishaana Sood, Gaurav K Garg, Birendra P Singh, Rajan Shukla, Priya A Reddy, Suzanne Gilbert, Ken Bassett, Gudlavalleti V S Murthy

    BACKGROUND A vision center (VC) is a significant eye care service model to strengthen primary eye care services. VCs have been set up at the block level, covering a population of 150,000-250,000 in rural areas in North India. Inadequate use by rural communities is a major challenge to sustainability of these VCs. This not only reduces the community’s vision improvement potential but also impacts self-sustainability and limits expansion of services in rural areas. The current literature reports a lack of awareness regarding eye diseases and the need for care, social stigmas, low priority being given to eye problems, prevailing gender discrimination, cost, and dependence on caregivers as factors preventing the use of primary eye care. OBJECTIVE Our organization is planning an awareness-cum-engagement intervention—door-to-door basic eye checkup and visual acuity screening in VCs coverage areas—to connect with the community and improve the rational use of VCs. METHODS In this randomized, parallel-group experimental study, we will select 2 VCs each for the intervention arm and the control arm from among poor, low-performing VCs (ie, walk-in of ≤10 patients/day) in our 2 operational regions (Vrindavan, Mathura District, and Mohammadi, Kheri District) of Uttar Pradesh. Intervention will include door-to-door screening and awareness generation in 8-12 villages surrounding the VCs, and control VCs will follow existing practices of awareness generation through community activities and health talks. Data will be collected from each VC for 4 months of intervention. Primary outcomes will be an increase in the number of walk-in patients, spectacle advise and uptake, referral and uptake for cataract and specialty surgery, and operational expenses. Secondary outcomes will be uptake of refraction correction and referrals for cataract and other eye conditions. Differences in the number of walk-in patients, referrals, uptake of services, and cost involved will be analyzed. RESULTS Background work involved planning of interventions and selection of VCs has been completed. Participant recruitment has begun and is currently in progress. CONCLUSIONS Through this study, we will analyze whether our door-to-door intervention is effective in increasing the number of visits to a VC and, thus, overall sustainability. We will also study the cost-effectiveness of this intervention to recommend its scalability. CLINICALTRIAL ClinicalTrials.gov NCT04800718; https://clinicaltrials.gov/ct2/show/NCT04800718 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/31951